Inhalation Sciences receives major IRS order for DissolvIt® from leading global pharma company

Inhalation Sciences Sweden AB (“ISAB”) has received a major Inhalation Research Services (IRS) order from a large global pharmaceutical company with commercial presence in more than 100 countries, including the US and Europe. The order value amounts to a total of EUR 224,555, corresponding to approximately SEK 2.45 million.

The assignment covers advanced in vitro dissolution testing using ISAB’s proprietary DissolvIt® technology, in which several different inhalation formulations will be evaluated and compared to generate high‑precision data that support the customer’s continued development and optimization of its inhaled drug candidates.

“We are very pleased to receive this substantial IRS order from a leading global pharmaceutical company. This project is an important validation of DissolvIt® as a high‑precision tool for comparing complex inhalation formulations in the preclinical phase, and the size and structure of the order, involving multiple formulations and study phases, confirms the growing demand for sophisticated dissolution testing in inhalation drug development”, says Manoush Masarrat, CEO of Inhalation Sciences.

For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.

This disclosure contains information that Inhalation Sciences is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on December 22, 2025 at 08:30.

Läs mer på Cision